The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
The grants are expected to be received over the next three years, commencing March 2022
Subscribe To Our Newsletter & Stay Updated
